Cellosaurus cell line LPS2 (CVCL_SA55)

PubMed=23230188; DOI=10.1158/2159-8290.CD-12-0197
Braas D., Ahler E., Tam B.M., Nathanson D., Riedinger M., Benz M.R., Smith K.B., Eilber F.C., Witte O.N., Tap W.D., Wu H., Christofk H.R.
Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment.
Cancer Discov. 2:1109-1117(2012)

PubMed=23416162; DOI=10.1016/j.ajpath.2013.01.002
Smith K.B., Tran L.M., Tam B.M., Shurell E.M., Li Y.-F., Braas D., Tap W.D., Christofk H.R., Dry S.M., Eilber F.C., Wu H.
Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition.
Am. J. Pathol. 182:1400-1411(2013)

PubMed=26643872; DOI=10.18632/oncotarget.6464
Kanojia D., Nagata Y., Garg M., Lee D.H., Sato A., Yoshida K., Sato Y., Sanada M., Mayakonda A., Bartenhagen C., Klein H.-U., Doan N.B., Said J.W., Mohith S., Gunasekar S., Shiraishi Y., Chiba K., Tanaka H., Miyano S., Myklebost O., Yang H., Dugas M., Meza-Zepeda L.A., Silberman A.W., Forscher C., Tyner J.W., Ogawa S., Koeffler H.P.
Genomic landscape of liposarcoma.
Oncotarget 6:42429-42444(2015)